192 related articles for article (PubMed ID: 31901768)
1. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK
Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768
[TBL] [Abstract][Full Text] [Related]
2. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
Laurie SA; Hao D; Leighl NB; Goffin J; Khomani A; Gupta A; Addison CL; Bane A; Seely J; Filion ML; Pond GR; Levine MN
Lung Cancer; 2017 Feb; 104():65-69. PubMed ID: 28213002
[TBL] [Abstract][Full Text] [Related]
4. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
Dudek AZ; Wang X; Gu L; Duong S; Stinchcombe TE; Kratzke R; Borghaei H; Vokes EE; Kindler HL
Clin Lung Cancer; 2020 Nov; 21(6):553-561.e1. PubMed ID: 32727707
[TBL] [Abstract][Full Text] [Related]
5. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
Ou SH; Moon J; Garland LL; Mack PC; Testa JR; Tsao AS; Wozniak AJ; Gandara DR
J Thorac Oncol; 2015 Feb; 10(2):387-91. PubMed ID: 25611229
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
Saka H; Kitagawa C; Kogure Y; Takahashi Y; Fujikawa K; Sagawa T; Iwasa S; Takahashi N; Fukao T; Tchinou C; Landers D; Yamada Y
Invest New Drugs; 2017 Aug; 35(4):451-462. PubMed ID: 28070720
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
[TBL] [Abstract][Full Text] [Related]
8. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
Laurie SA; Gupta A; Chu Q; Lee CW; Morzycki W; Feld R; Foo AH; Seely J; Goffin JR; Laberge F; Murray N; Rao S; Nicholas G; Laskin J; Reiman T; Sauciuc D; Seymour L
J Thorac Oncol; 2011 Nov; 6(11):1950-4. PubMed ID: 22005473
[TBL] [Abstract][Full Text] [Related]
9. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
[TBL] [Abstract][Full Text] [Related]
10. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
11. Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
Ikeda T; Takemoto S; Senju H; Gyotoku H; Taniguchi H; Shimada M; Dotsu Y; Umeyama Y; Tomono H; Kitazaki T; Fukuda M; Soda H; Yamaguchi H; Fukuda M; Mukae H
Thorac Cancer; 2020 Jul; 11(7):1972-1978. PubMed ID: 32462731
[TBL] [Abstract][Full Text] [Related]
12. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
13. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
Cortinovis D; Grosso F; Carlucci L; Zucali PA; Pasello G; Tiseo M; Sperandi F; Hollander L; Galli F; Torri V; Rulli E; Canova S; Maconi A; Bidoli P; Ceresoli GL; D'Incalci M;
Clin Lung Cancer; 2021 Jul; 22(4):361-370.e3. PubMed ID: 32732073
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Douma LH; Lalezari F; van der Noort V; de Vries JF; Monkhorst K; Smesseim I; Baas P; Schilder B; Vermeulen M; Burgers JA; de Gooijer CJ
Lancet Oncol; 2023 Nov; 24(11):1219-1228. PubMed ID: 37844598
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; De Vincenzo F; Giordano L; Cordua N; D'Antonio F; Santoro A
Lung Cancer; 2020 Apr; 142():132-137. PubMed ID: 32102735
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Papa S; Popat S; Shah R; Prevost AT; Lal R; McLennan B; Cane P; Lang-Lazdunski L; Viney Z; Dunn JT; Barrington S; Landau D; Spicer J
J Thorac Oncol; 2013 Jun; 8(6):783-7. PubMed ID: 23571475
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR
J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]